학술논문
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Original Article
Original Article
Document Type
Report
Author
Gonzalez-Martin, Antonio; Pothuri, Bhavana; Vergote, Ignace; DePont Christensen, Rene; Graybill, Whitney; Mirza, Mansoor R.; McCormick, Colleen; Lorusso, Domenica; Hoskins, Paul; Freyer, Gilles; Baumann, Klaus; Jardon, Kris; Redondo, Andres; Moore, Richard G.; Vulsteke, Christof; O'Cearbhaill, Roisin E.; Lund, Bente; Backes, Floor; Barretina-Ginesta, Pilar; Haggerty, Ashley F.; Rubio-Perez, Maria J.; Shahin, Mark S.; Mangili, Giorgia; Bradley, William H.; Bruchim, Ilan; Sun, Kaiming; Malinowska, Izabela A.; Li, Yong; Gupta, Divya; Monk, Bradley J.
Source
The New England Journal of Medicine. Dec 19, 2019, Vol. 381 Issue 25, p2391, 12 p.
Subject
Language
English
ISSN
0028-4793
Abstract
Niraparib in patients with newly diagnosed advanced ovarian cancer had significantly longer progression-free survival than those who received placebo. Of the 733 patients who underwent randomization, 373 had tumors with homologous-recombination deficiency. At the 24-month interim analysis, the rate of overall survival was 84% in the niraparib group and 77% in the placebo group.